Imatinibis an oral medication used to treat chronic myeloid leukemia (CML) in adult patients who are positive for the Philadelphia chromosome (Ber-Abl). Imatinib 152459-95-5 Imatinib Mesylate 220127-57-1 Imatinib Intermediate 1 106261-49-8 Imatinib Intermediate 2 106261-48-7 Imatinib Intermediate ...
How to kill CML cells after imatinib failuredoi:10.1097/01.OTU.0000411008.72419.c4&NAOncology Times
HSCT: How Does It Work? Letizia Galgano and Daphna Hutt 2 Abstract The HSCT (haematopoietic stem cell transplant) is a particular treatment for many haematological and non-haematological diseases. Broadly, there are three different categories of transplantation, autologous, allogeneic and syn-...
down-regulation of immunogenic antigens on the CML cells in response to imatinib treatment, which results in the inhibition of CML-directed immune responses... KM Brauer,D Werth,K Von Schwarzenberg,... - 《Cancer Research》 被引量: 172发表: 2007年 Lonafarnib reduces the resistance of primitive...
In our laboratory, instead, a stem cell-selective oxygen concentration (see above) was used to investigate leukemia stem cells (LSCs) of chronic myeloid leukemia (CML), and in particular their sensitivity to the tyrosine-kinase inhibitor (TKi) imatinib mesylate (IM) (Gleevec®; Novartis, East...
aVEENAT (Imatinib mesylate) is indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 正在翻译,请等待...[translate] ...
It provided the rationale for producing first imatinib and then a series of small molecules designed to inhibit the tyrosine kinase activity of the Bcr-Abl oncoprotein, all of which can induce complete cytogenetic remissions in the majority of patients with chronic myelogenous leukemia (CML) in the...
It provided the rationale for producing first imatinib and then a series of small molecules designed to inhibit the tyrosine kinase activity of the Bcr-Abl oncoprotein, all of which can induce complete cytogenetic remissions in the majority of patients with chronic...